<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116360</article-id><article-id pub-id-type="publisher-id">ACM-42927</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_21372398.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Ki-67在肝细胞癌并微血管癌栓中表达的意义
  Significance of Ki-67 Expression in Hepatocellular Carcinoma with Microvascular Tumor Thrombus
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>翔宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>奎</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>坤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>解</surname><given-names>宇威</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>瑞谦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>仲</surname><given-names>灏辰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>艾</surname><given-names>宪程</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曹</surname><given-names>景玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2507</fpage><lpage>2513</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨Ki-67在肝细胞癌微血管侵犯(微血管侵犯：MVI)中表达的意义。方法：对青岛大学附属医院从2013年1月到2020年6月进行的约680例行根治性肝切除手术并确诊为肝细胞癌的患者的临床及病理资料进行回顾性分析。结果：这680例患者中，MVI阳性的患者占53.2% (362/680)。通过单因素分析，发现MVI的发生与Ki-67阳性有关，此外还有患者的年龄、性别、饮酒史、术前白蛋白、甲胎蛋白(AFP)、癌抗原125 (CA125)、谷草转氨酶(AST)、γ-谷氨酰转肽酶、肿瘤最大直径、肿瘤数目、是否存在卫星结节与MVI的发生有关(均P &lt; 0.05)。多因素Logistic回归分析结果显示：Ki-67是MVI的独立危险因素。MVI的其他独立危险因素还包括AST、性别，肿瘤直径 &gt; 3 cm，存在卫星结节(均P &lt; 0.05)。结论：Ki-67的高表达(≥20%)与MVI的发生有关。
   Objective: To investigate the significance of Ki-67 expression in microvascular invasion (MVI) of HCC. Methods: The clinical and pathological data of 680 patients with liver cancer diagnosed as HCC were analyzed retrospectively from January 2013 to June 2020 in the Affiliated Hospital of Qingdao University. Results: Among the 680 patients, 53.2% (362/680) of the patients were with MVI positive. The results showed that MVI was related to Ki-67 positive by single factor analysis. In addition, the age, sex, drinking history, preoperative albumin, AFP, CA125, AST, and the age of the patients, γ-glutamyl transpeptidase, the largest diameter of tumor, the number of tumors and the presence of satellite nodules were also observed related to the occurrence of MVI (P &lt; 0.05). The results of multivariate logistic regression analysis showed that Ki-67 was an independent risk factor for MVI. Other independent risk factors of MVI included AST, sex, tumor diameter &gt; 3 cm, satellite nodule (P &lt; 0.05). Conclusion: The high expression of Ki-67 (≥20%) is associated with MVI.
 
</p></abstract><kwd-group><kwd>肝细胞癌，Ki-67，MVI, Hepatocellular Carcinoma</kwd><kwd> Ki-67</kwd><kwd> MVI</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨Ki-67在肝细胞癌微血管侵犯(微血管侵犯：MVI)中表达的意义。方法：对青岛大学附属医院从2013年1月到2020年6月进行的约680例行根治性肝切除手术并确诊为肝细胞癌的患者的临床及病理资料进行回顾性分析。结果：这680例患者中，MVI阳性的患者占53.2% (362/680)。通过单因素分析，发现MVI的发生与Ki-67阳性有关，此外还有患者的年龄、性别、饮酒史、术前白蛋白、甲胎蛋白(AFP)、癌抗原125 (CA125)、谷草转氨酶(AST)、γ-谷氨酰转肽酶、肿瘤最大直径、肿瘤数目、是否存在卫星结节与MVI的发生有关(均P &lt; 0.05)。多因素Logistic回归分析结果显示：Ki-67是MVI的独立危险因素。MVI的其他独立危险因素还包括AST、性别，肿瘤直径 &gt; 3 cm，存在卫星结节(均P &lt; 0.05)。结论：Ki-67的高表达(≥20%)与MVI的发生有关。</p></sec><sec id="s2"><title>关键词</title><p>肝细胞癌，Ki-67，MVI</p></sec><sec id="s3"><title>Significance of Ki-67 Expression in Hepatocellular Carcinoma with Microvascular Tumor Thrombus</title><p>Xiangyu Xu, Kui Liu, Kun Li, Peng Liu, Yuwei Xie, Ruiqian Gao, Jing Wang, Haochen Zhong, Xiancheng Ai, Jingyu Cao<sup>*</sup></p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/2-1572274x4_hanspub.png" /></p><p>Received: May 1<sup>st</sup>, 2021; accepted: May 13<sup>th</sup>, 2021; published: Jun. 7<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-1572274x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the significance of Ki-67 expression in microvascular invasion (MVI) of HCC. Methods: The clinical and pathological data of 680 patients with liver cancer diagnosed as HCC were analyzed retrospectively from January 2013 to June 2020 in the Affiliated Hospital of Qingdao University. Results: Among the 680 patients, 53.2% (362/680) of the patients were with MVI positive. The results showed that MVI was related to Ki-67 positive by single factor analysis. In addition, the age, sex, drinking history, preoperative albumin, AFP, CA125, AST, and the age of the patients, γ-glutamyl transpeptidase, the largest diameter of tumor, the number of tumors and the presence of satellite nodules were also observed related to the occurrence of MVI (P &lt; 0.05). The results of multivariate logistic regression analysis showed that Ki-67 was an independent risk factor for MVI. Other independent risk factors of MVI included AST, sex, tumor diameter &gt; 3 cm, satellite nodule (P &lt; 0.05). Conclusion: The high expression of Ki-67 (≥20%) is associated with MVI.</p><p>Keywords:Hepatocellular Carcinoma, Ki-67, MVI</p><disp-formula id="hanspub.42927-formula14"><graphic xlink:href="//html.hanspub.org/file/2-1572274x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1572274x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1572274x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝细胞癌(hepatocellular carcinoma, HCC)是世界上危害性最强的癌症之一，其死亡率以及发病率逐年升高 [<xref ref-type="bibr" rid="hanspub.42927-ref1">1</xref>]。在我国，它已经成为最常见的、危害最强的肿瘤之一。肝细胞癌的主要治疗方法包括根治性手术(肝切除、肝移植、以及射频消融)、姑息性治疗(经动脉化疗栓塞、免疫治疗、分子靶向治疗) [<xref ref-type="bibr" rid="hanspub.42927-ref2">2</xref>]。但极高的复发率仍然限制着患者的生存时间和生活质量 [<xref ref-type="bibr" rid="hanspub.42927-ref3">3</xref>]。而微血管侵犯(MVI)被证明是肝细胞癌复发的重要因素；MVI的发生提示，肝癌细胞正在侵犯周围组织、血管，并进行远处转移；而这被认为是术后复发的重要机制，同时也是低存活率的独立危险因素 [<xref ref-type="bibr" rid="hanspub.42927-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.42927-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.42927-ref6">6</xref>]。与细胞增殖相关的重要指标中Ki-67抗原是其中之一，它是一种与细胞周期密切相关的增殖细胞核抗原，它与细胞DNA半保留复制相偶联，这提示了Ki-67可能是保持细胞增殖所必须的 [<xref ref-type="bibr" rid="hanspub.42927-ref7">7</xref>]。Ki-67抗原的表达可以反映肿瘤细胞的增殖活性，与恶性肿瘤的发生、发展、转移以及预后密切相关 [<xref ref-type="bibr" rid="hanspub.42927-ref8">8</xref>]。本研究旨在探讨Ki-67的表达水平与MVI的发生的相关性，以期为分析和评估肝细胞癌患者的预后提供依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>本研究从2013年1月到2020年6月在青岛大学附属医院共1000余例行手术切除的肝癌患者中，最终纳入680例患者。其中男性患者553例，女性患者127例。男性患者占81.3%；其平均年龄为60岁。纳入标准：1) 术前诊断为肝细胞癌并行根治性切除手术；2) 术后病理学证实为肝细胞癌；3) 未出现肝外转移；4) 临床病理信息完整且无其他肿瘤病史。排除标准：1) 术前曾行肝动脉化疗栓塞术(TACE)或放射性治疗；2) 根治性手术前行射频消融手术；3) 无法行根治性手术；4) 临床资料或病理信息不完整。本研究经青岛大学附属医院伦理委员会审核批准。本研究参与者或其法定监护人均已在研究登记前签署了书面知情同意书。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>本研究收集患者一般临床资料及病理资料。分别比较MVI阳性患者与MVI阴性患者临床及病理参数差异。参数包括：Ki-67、年龄、性别、饮酒史、乙肝病史、ALT、AST、GGT、AFP、CEA、CA125、CA199、ALB、TB、肿瘤直径、肿瘤数量、肝硬化、卫星结节。肝癌根治性切除标准符合《原发性肝癌诊疗规范(2019年版)》 [<xref ref-type="bibr" rid="hanspub.42927-ref9">9</xref>]。MVI的诊断根据《原发性肝癌规范化病理诊断指南(2015年版)》 [<xref ref-type="bibr" rid="hanspub.42927-ref10">10</xref>]。</p></sec><sec id="s6_3"><title>2.3. Ki-67的确定</title><p>将患者的术后标本常规甲醛固定，24小时内取材，石蜡包埋，连续5 μm厚度切片，苏木精-伊红(HE)染色。采用鼠抗人Ki67单克隆抗体、SP免疫组化试剂盒，并按照说明书操作进行免疫组化染色，在显微镜下Ki-67染色呈棕色或黄色。结果判读：由两名高年资的病理医师分别读片，高倍镜下随机选取5个不同的视野，每个视野计数200个细胞，计算阳性细胞所占百分比。通过ROC曲线(receiver operator characteristic curve)确定20%为Ki-67表达的最佳临界值，并以此进行分组：将Ki-67阳性细胞占比 &lt; 20%为低表达组；Ki67阳性细胞占比 ≥ 20%为Ki-67高表达组。</p></sec><sec id="s6_4"><title>2.4. 统计学处理</title><p>本研究均使用spss25.0软件进行计算。首先对分类资料进行Pearson χ&#178;检验。用多因素二元Logistics回归分析进行多因素分析。P &lt; 0.05均被认为具有统计学意义，以此来确定影响MVI发生的保护因素及独立危险因素。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料</title><p>680例患者中，MVI阳性的患者占53.2%。MVI阴性组男性患者245例，女性患者73例，男性患者占77.04%；年龄37~87岁，平均年龄60岁。MVI阳性组男性患者308例，女性患者54例，男性患者占85.08%；年龄32~84岁，平均年龄58岁。61.9% (421/680)的患者有Ki-67阳性，其余259例(38.1%)患者Ki-67阴性。</p></sec><sec id="s7_2"><title>3.2. 单因素方差分析Ki-67阳性及肿瘤相关因素对MVI形成的影响：</title><p>通过对分类资料进行χ&#178;检验，结果示Ki-67的阳性率在MVI阳性组明显高于MVI阴性组(P &lt; 0.05)，MVI阳性组和MVI阴性组Ki-67阳性率分别为62.2% (262/421)和38.6% (100/259)。同时患者的年龄、性别、血清白蛋白、肿瘤最大直径、肿瘤数目、是否存在卫星结节等因素也在两组中具有统计学意义(表1)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Univariate analysis of the relationship between Ki-67, tumor related factors and MV</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" >MVI阳性组(n = 362)</th><th align="center" valign="middle" >MVI阴性组(n = 318)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle"  colspan="5"  >一般资料</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >年龄(岁)</td><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >271</td><td align="center" valign="middle" >274</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >≤50</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >44</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >性别</th><th align="center" valign="middle" >男</th><th align="center" valign="middle" >308</th><th align="center" valign="middle" >245</th><th align="center" valign="middle"  rowspan="2"  >0.007</th></tr></thead><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >73</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >KI-67</td><td align="center" valign="middle" >&gt;20</td><td align="center" valign="middle" >262</td><td align="center" valign="middle" >159</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >≤20</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >159</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >乙肝病史</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >277</td><td align="center" valign="middle" >240</td><td align="center" valign="middle"  rowspan="2"  >0.750</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >78</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >饮酒史</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >137</td><td align="center" valign="middle" >129</td><td align="center" valign="middle"  rowspan="2"  >0.468</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >225</td><td align="center" valign="middle" >189</td></tr><tr><td align="center" valign="middle"  colspan="5"  >术前实验室检查</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >AFP</td><td align="center" valign="middle" >&gt;400</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >65</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >≤400</td><td align="center" valign="middle" >227</td><td align="center" valign="middle" >253</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CEA</td><td align="center" valign="middle" >&gt;3.4</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >78</td><td align="center" valign="middle"  rowspan="2"  >0.508</td></tr><tr><td align="center" valign="middle" >≤3.4</td><td align="center" valign="middle" >281</td><td align="center" valign="middle" >240</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CA199</td><td align="center" valign="middle" >&gt;39</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >59</td><td align="center" valign="middle"  rowspan="2"  >0.332</td></tr><tr><td align="center" valign="middle" >≤39</td><td align="center" valign="middle" >284</td><td align="center" valign="middle" >259</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >CA125</td><td align="center" valign="middle" >&gt;35</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >15</td><td align="center" valign="middle"  rowspan="2"  >0.034</td></tr><tr><td align="center" valign="middle" >≤35</td><td align="center" valign="middle" >330</td><td align="center" valign="middle" >303</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >白蛋白</td><td align="center" valign="middle" >&gt;35</td><td align="center" valign="middle" >328</td><td align="center" valign="middle" >303</td><td align="center" valign="middle"  rowspan="2"  >0.019</td></tr><tr><td align="center" valign="middle" >≤35</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >15</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >总胆红素</td><td align="center" valign="middle" >&gt;20</td><td align="center" valign="middle" >146</td><td align="center" valign="middle" >111</td><td align="center" valign="middle"  rowspan="2"  >0.145</td></tr><tr><td align="center" valign="middle" >≤20</td><td align="center" valign="middle" >216</td><td align="center" valign="middle" >207</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >ALT</td><td align="center" valign="middle" >&gt;40</td><td align="center" valign="middle" >128</td><td align="center" valign="middle" >102</td><td align="center" valign="middle"  rowspan="2"  >0.367</td></tr><tr><td align="center" valign="middle" >≤40</td><td align="center" valign="middle" >234</td><td align="center" valign="middle" >216</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >AST</td><td align="center" valign="middle" >&gt;40</td><td align="center" valign="middle" >103</td><td align="center" valign="middle" >56</td><td align="center" valign="middle"  rowspan="2"  >0.001</td></tr><tr><td align="center" valign="middle" >≤40</td><td align="center" valign="middle" >259</td><td align="center" valign="middle" >262</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >GGT</td><td align="center" valign="middle" >&gt;60</td><td align="center" valign="middle" >136</td><td align="center" valign="middle" >81</td><td align="center" valign="middle"  rowspan="2"  >0.001</td></tr><tr><td align="center" valign="middle" >≤60</td><td align="center" valign="middle" >226</td><td align="center" valign="middle" >237</td></tr><tr><td align="center" valign="middle"  colspan="5"  >病理学检查</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肿瘤最大直径</td><td align="center" valign="middle" >&gt;3</td><td align="center" valign="middle" >260</td><td align="center" valign="middle" >172</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >≤3</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >146</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肿瘤数目</td><td align="center" valign="middle" >&gt;1</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >22</td><td align="center" valign="middle"  rowspan="2"  >0.005</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >313</td><td align="center" valign="middle" >296</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肝硬化</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >223</td><td align="center" valign="middle" >209</td><td align="center" valign="middle"  rowspan="2"  >0.265</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >139</td><td align="center" valign="middle" >109</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >卫星结节</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >16</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >286</td><td align="center" valign="middle" >302</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. KI-67及肿瘤相关因素与MVI形成关系的单因素分析[n(%)]</p></sec><sec id="s7_3"><title>3.3. 对MVI的独立影响因素进行多因素二元Logistics回归分析</title><p>为进一步分析Ki-67与MVI的相关性，对单因素方差检验有意义的因素进行多因素Logistic回归分析，发现Ki-67阳性是肝癌MVI的独立危险因素(OR = 1.024, P = 0.000)，此外，AST、男性患者、肿瘤直径、存在卫星结节是MVI发生的重要影响因素(P均 &lt; 0.05) (表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Logistic regression analysis of independent influencing factors of MV</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >B</th><th align="center" valign="middle"  rowspan="2"  >标准误差</th><th align="center" valign="middle"  rowspan="2"  >瓦尔德</th><th align="center" valign="middle"  rowspan="2"  >自由度</th><th align="center" valign="middle"  rowspan="2"  >显著性</th><th align="center" valign="middle"  rowspan="2"  >Exp(B)</th><th align="center" valign="middle"  colspan="2"  >EXP(B)的95%置信区间</th></tr></thead><tr><td align="center" valign="middle" >因素</td><td align="center" valign="middle" >下限</td><td align="center" valign="middle" >上限</td></tr><tr><td align="center" valign="middle" >ki67</td><td align="center" valign="middle" >0.024</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >33.964</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >1.024</td><td align="center" valign="middle" >1.016</td><td align="center" valign="middle" >1.032</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >−0.026</td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" >8.152</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >0.974</td><td align="center" valign="middle" >0.957</td><td align="center" valign="middle" >0.992</td></tr><tr><td align="center" valign="middle" >性别(1：男；0：女)</td><td align="center" valign="middle" >0.646</td><td align="center" valign="middle" >0.243</td><td align="center" valign="middle" >7.079</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.008</td><td align="center" valign="middle" >1.908</td><td align="center" valign="middle" >1.186</td><td align="center" valign="middle" >3.072</td></tr><tr><td align="center" valign="middle" >病灶数(0：=1；1：≥1)</td><td align="center" valign="middle" >0.469</td><td align="center" valign="middle" >0.303</td><td align="center" valign="middle" >2.392</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.122</td><td align="center" valign="middle" >1.598</td><td align="center" valign="middle" >0.882</td><td align="center" valign="middle" >2.894</td></tr><tr><td align="center" valign="middle" >卫星结节(0：无；1：有)</td><td align="center" valign="middle" >1.416</td><td align="center" valign="middle" >0.307</td><td align="center" valign="middle" >21.217</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >4.122</td><td align="center" valign="middle" >2.256</td><td align="center" valign="middle" >7.53</td></tr><tr><td align="center" valign="middle" >肿瘤最大直径</td><td align="center" valign="middle" >0.141</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >17.711</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >1.151</td><td align="center" valign="middle" >1.078</td><td align="center" valign="middle" >1.229</td></tr><tr><td align="center" valign="middle" >GGT</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.61</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.435</td><td align="center" valign="middle" >1.001</td><td align="center" valign="middle" >0.999</td><td align="center" valign="middle" >1.003</td></tr><tr><td align="center" valign="middle" >AST</td><td align="center" valign="middle" >0.011</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >4.699</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.030</td><td align="center" valign="middle" >1.011</td><td align="center" valign="middle" >1.001</td><td align="center" valign="middle" >1.021</td></tr><tr><td align="center" valign="middle" >ALB</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >0.013</td><td align="center" valign="middle" >0.122</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.727</td><td align="center" valign="middle" >1.004</td><td align="center" valign="middle" >0.98</td><td align="center" valign="middle" >1.03</td></tr><tr><td align="center" valign="middle" >AFP</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >3.741</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.053</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >CA125</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >0.453</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.501</td><td align="center" valign="middle" >1.002</td><td align="center" valign="middle" >0.997</td><td align="center" valign="middle" >1.007</td></tr></tbody></table></table-wrap><p>表2. MVI独立影响因素的Logistic回归分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>肝癌根治性切除后患者的复发情况直接影响患者的生存时间和生存治疗，而MVI阳性同样对肝细胞癌患者术后复发具有极大的影响，很多MVI阳性的患者病情短时间即可快速进展。何旭昶等 [<xref ref-type="bibr" rid="hanspub.42927-ref11">11</xref>] 报道，通过两年的随访，100例接受根治性切除的肝细胞癌患者中，53例MVI阳性患者中有31例(58.4%) 2年内复发，而47例MVI阴性的患者中仅有18例(38.2%) 2年内复发。李彦龙 [<xref ref-type="bibr" rid="hanspub.42927-ref12">12</xref>] 报道，78例孤立性肝细胞癌根治性切除术后患者，其中MVI阳性患者术后2年无瘤生存率为45.8%，MVI阴性患者术后2年无瘤生存率为90.7%。肝细胞癌肝切除术后复发专家共识 [<xref ref-type="bibr" rid="hanspub.42927-ref13">13</xref>] 表示MVI是HCC肝切除术后早期复发的高危因素，并将伴有MVI的肿瘤列为复发高风险。各项研究普遍认为，MVI阳性患者，肝癌术后复发时间较阴性组短，血管侵犯、肝内外转移几率明显升高。故MVI阳性可能预示HCC患者术后更短的无瘤生存期以及更高的肿瘤术后复发率，并将是否存在MVI列为预测HCC术后无瘤生存期和复发的重要指标。</p><p>肿瘤的增殖对HCC术后患者的复发和转移有很大的影响。Ki-67与细胞的增殖密切相关，周期性表达于细胞增殖过程，与DNA的合成与复制密切相关，而其半衰期短的特点可准确反映肿瘤细胞的增殖速率，故已成为重要的检测肿瘤细胞增殖活性的组织学指标。研究认为，Ki-67指数越高，肿瘤增殖速度越快，肿瘤的恶性程度越高，肿瘤分期较晚，无瘤生存及生存率越低 [<xref ref-type="bibr" rid="hanspub.42927-ref14">14</xref>]。Ki-67已广泛应用于对乳腺癌、卵巢癌、宫颈癌、胃癌、食管癌的恶性程度与预后的分析 [<xref ref-type="bibr" rid="hanspub.42927-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42927-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42927-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.42927-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.42927-ref19">19</xref>]。贾磊等研究显示肝癌患者复发组Ki-67明显高于治愈组 [<xref ref-type="bibr" rid="hanspub.42927-ref20">20</xref>]。王凝芳 [<xref ref-type="bibr" rid="hanspub.42927-ref21">21</xref>] 的研究发现，Ki-67阳性患者无瘤生存期远低于阴性患者。孙树刚 [<xref ref-type="bibr" rid="hanspub.42927-ref22">22</xref>] 研究发现，Ki-67阴性患者术后1年复发率为27.0% (47/174)，阳性患者术后1年复发率为46.9% (38/81)。肝癌患者术后的复发、转移严重限制了患者的长期生存以及生活质量。众多研究表明在肝细胞癌中Ki-67高表达为术后复发的高危因素，Ki-67高表达的肝癌肿瘤常常增长迅速，恶性程度高，侵犯血管能力及肝内、外转移能力强，并会明显缩短患者的无瘤生存时间与总生存期。故此对于Ki-67的检测已被广泛应用于多种恶性肿瘤进展的预测 [<xref ref-type="bibr" rid="hanspub.42927-ref23">23</xref>]。对肝细胞癌患者的肿瘤标本进行Ki-67的检测可提高临床对肝癌患者根治性切除术后无瘤生存和复发的预测准确率，并对高复发风险的患者进行跟踪随访、及早干涉，进一步提高患者生存质量及生存时间。</p><p>本研究通过对680例患者进行根治性切除并病理确诊为肝细胞癌的患者进行回顾性分析，发现，Ki-67的发生与MVI的发生密切相关。Ki-67的高表达是MVI发生的独立危险因素。肝癌细胞的快速增殖，可引起Ki-67高表达，Ki-67的高表达提示肝细胞癌的侵袭能力增强，而MVI (微血管侵犯)正是被认为是肝细胞癌的增长和肝内转移的重要因素 [<xref ref-type="bibr" rid="hanspub.42927-ref24">24</xref>]。Ki-67的高表达可能直接或间接作用于MVI阳性的肝癌肿瘤，促进肝癌细胞增殖，而引起肝癌患者术后的复发与转移。MVI阳性合并Ki-67高表达的患者，可能存在肝细胞癌恶性程度高、侵袭能力强，术后复发、转移等风险。Ki-67的高表达与MVI的发生的相关性是显著的。联合检测MVI与Ki-67抗原，可能有利于综合评估肝癌的复发与转移的风险，并有助于对HCC术后患者进行更为精准的分期与预后评估，加强对高危患者的早期复发转移的发现与干预，以提高患者的生存时间与生存质量。本研究的局限性：未对680例患者进行无瘤生存及复发的统计，未进行生存分析，无法验证联合检测Ki-67与MVI对肝细胞癌患者无瘤生存及复发情况预测的合理性，但本研究证实了Ki-67高表达与MVI的发生密切相关。未进行生存分析对本研究影响较小。</p><p>综上所述，Ki-67的高表达(≥20%)与MVI的发生有关。</p></sec><sec id="s9"><title>文章引用</title><p>徐翔宇,刘 奎,李 坤,刘 鹏,解宇威,高瑞谦,王 晶,仲灏辰,艾宪程,曹景玉. Ki-67在肝细胞癌并微血管癌栓中表达的意义Significance of Ki-67 Expression in Hepatocellular Carcinoma with Microvascular Tumor Thrombus[J]. 临床医学进展, 2021, 11(06): 2507-2513. https://doi.org/10.12677/ACM.2021.116360</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42927-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Q., et al. (2020) SSH3 Promotes Malignant Progression of HCC by Activating FGF1-Mediated FGF/FGFR Pathway. European Review for Medical and Pharmacological Sciences, 24, 11561-11568.</mixed-citation></ref><ref id="hanspub.42927-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ziogas, I. and Tsoulfas, G. (2017) Advances and Challenges in Laparoscopic Surgery in the Management of Hepatocellular Carcinoma. World Journal of Gastrointestinal Surgery, 9, 233-245. &lt;br&gt;https://doi.org/10.4240/wjgs.v9.i12.233</mixed-citation></ref><ref id="hanspub.42927-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zeng, H., et al. (2018) Changing Cancer Survival in China during 2003-15: A Pooled Analysis of 17 Population-Based Cancer Registries. The Lancet Global Health, 6, e555-e567. &lt;br&gt;https://doi.org/10.1016/S2214-109X(18)30127-X</mixed-citation></ref><ref id="hanspub.42927-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Z., et al. (2012) Long-Term Outcomes of Repeat Hepatic Resection in Patients with Recurrent Hepatocellular Carcinoma and Analysis of Recurrent Types and Their Prognosis: A Single-Center Experience in China. Annals of Surgical Oncology, 19, 2515-2525. &lt;br&gt;https://doi.org/10.1245/s10434-012-2269-7</mixed-citation></ref><ref id="hanspub.42927-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Neumann, U. (2011) Outcome after Partial Hepatectomy for Hepatocellular Cancer within the Milan Criteria. The British Journal of Surgery, 98, 1300-1301. &lt;br&gt;https://doi.org/10.1002/bjs.7625</mixed-citation></ref><ref id="hanspub.42927-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., et al. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews. Gastroenterology &amp; Hepatology, 16, 589-604. &lt;br&gt;https://doi.org/10.1038/s41575-019-0186-y</mixed-citation></ref><ref id="hanspub.42927-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gerdes, J., et al. (1983) Production of a Mouse Monoclonal Antibody Reactive with a Human Nuclear Antigen Associated with Cell Proliferation. International Journal of Cancer, 31, 13-20. &lt;br&gt;https://doi.org/10.1002/ijc.2910310104</mixed-citation></ref><ref id="hanspub.42927-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">廖谦和, 等. 子宫颈癌及癌前病变HPV16、Ki-67的表达及其相关性[J]. 临床与实验病理学杂志, 2007(3): 297-299.</mixed-citation></ref><ref id="hanspub.42927-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">原发性肝癌诊疗规范(2019年版) [J]. 中国临床医学, 2020, 27(1): 140-160.</mixed-citation></ref><ref id="hanspub.42927-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">吴孟超, 等. 原发性肝癌规范化病理诊断指南(2015年版) [J]. 临床肝胆病杂志, 2015, 31(6): 833-839.</mixed-citation></ref><ref id="hanspub.42927-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">何旭昶, 等. 微血管侵犯分级对肝细胞癌行根治性肝切除术后早期复发的预测价值[J]. 临床肝胆病杂志, 2020, 36(8): 1757-1762.</mixed-citation></ref><ref id="hanspub.42927-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李彦龙, 张媛, 王逢茂. 术前CT征象对孤立性肝癌微血管侵犯及术后早期复发的预测分析[J]. 中国CT和MRI杂志, 2021, 19(1): 113-116.</mixed-citation></ref><ref id="hanspub.42927-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">夏勇, 杨田, 王葵. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版) [J]. 中国实用外科杂志, 2021, 41(1): 20-30.</mixed-citation></ref><ref id="hanspub.42927-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lim, M., et al. (2011) Predictable Factors for Lymph Node Metastasis in Early Gastric Cancer-Analysis of Single Institutional Experience. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 15, 1783-1788. &lt;br&gt;https://doi.org/10.1007/s11605-011-1624-5</mixed-citation></ref><ref id="hanspub.42927-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">崔凯, 张利平. p16蛋白、Ki67抗原检测在宫颈上皮内瘤变中的诊断价值[J]. 检验医学与临床, 2019, 16(24): 3704-3706.</mixed-citation></ref><ref id="hanspub.42927-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">贺红梅, 等. IMP3、P16、HE4、Ki67、P53在卵巢浆液性肿瘤中表达的生物学意义、鉴别诊断及预后的研究[J]. 临床和实验医学杂志, 2020, 19(23): 2537-2540.</mixed-citation></ref><ref id="hanspub.42927-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">李文华, 张莹. 乳腺癌复发转移灶与原发灶中ER、PR、HER-2、p53、Ki-67的表达差异[J]. 临床与实验病理学杂志, 2016, 32(7): 727-730.</mixed-citation></ref><ref id="hanspub.42927-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">齐兴峰, 等. 食管癌组织中Ki-67和VEGF的表达及其与放疗预后的关系[J]. 临床合理用药杂志, 2019, 12(34): 44-46+48.</mixed-citation></ref><ref id="hanspub.42927-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">王娜, 等. NEDD9、Ki67、P53联合检测对胃癌的早期诊断和恶性程度评估的价值[J]. 实用医学杂志, 2017, 33(12): 1961-1965.</mixed-citation></ref><ref id="hanspub.42927-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">贾磊, 等. CD34和Ki67的表达预测肝癌术后复发的风险[J]. 肝脏, 2020, 25(2): 197-199.</mixed-citation></ref><ref id="hanspub.42927-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">王凝芳, 等. Ki-67在肝细胞肝癌中的表达及其临床意义[J]. 大连大学学报, 2003(2): 71-73+79.</mixed-citation></ref><ref id="hanspub.42927-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">孙树刚, 等. 肝细胞癌E-cadherin和ki-67蛋白表达与肝切除术预后关系的研究[J]. 中国现代普通外科进展, 2010, 13(2): 125-128.</mixed-citation></ref><ref id="hanspub.42927-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">张景丽, 等. 乳腺癌Ki-67及PCNA表达的比较研究[J]. 临床与实验病理学杂志, 2003(1): 70-72.</mixed-citation></ref><ref id="hanspub.42927-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Imamura, H., et al. (2003) Risk Factors Contributing to Early and Late Phase Intrahepatic Recurrence of Hepatocellular Carcinoma after Hepatectomy. Journal of Hepatology, 38, 200-207.  
&lt;br&gt;https://doi.org/10.1016/S0168-8278(02)00360-4</mixed-citation></ref></ref-list></back></article>